In the first full-scale revision since 2004, new guidelines for the management of ST-segment elevation myocardial infarction (STEMI) focus on clinical decision making at all stages, from early ...

Unrecognized MI Prevalent in Older Adults, Ups Mortality New guidelines urge timely management for patients with ST-segment elevation myocardial infarction (STEMI). (HealthDay News) – New guidelines ...

The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary ...

Nobody can debate that PCI is associated with better outcomes than fibrinolytics in patients with STEMI. However, it is reasonable to question the continual use of fixed time windows (90 minutes or ...

BARCELONA, Spain—The European Society of Cardiology (ESC) has issued new guidelines for the management of acute MI patients presenting with ST-segment elevation, placing a new emphasis on the use of ...

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised “Guidelines on the Management ...

August 26, 2012 (Munich, Germany) — Authors of the new European Society of Cardiology (ESC) guidelines for the management of patients with acute ST-elevation MI (STEMI) hope their recommendations spur ...

New guidelines published online today in Circulation and the Journal of the American College of Cardiology provide an efficient overview of the best treatments for STEMI patients. (Click here to ...

Peter Bogaty and colleagues,1 in their review of the American College of Cardiology/American Heart Association STEMI guidelines from a Canadian perspective, recommend transfer of STEMI patients with ...

Please provide your email address to receive an email when new articles are posted on . New guidelines aimed at improving and streamlining care for patients with STEMI were published online today in ...

Competing interests: None declared for Drs. Bogaty and O'Neill. Dr. Armstrong has received research funding from Hoffmann–La Roche, Aventis and Boehringer Ingelheim, and educational and consultant ...